Fast Facts: Biosimilars
By P. Cornes and D.J. Bennett
()
About this ebook
Read more from P. Cornes
Fast Facts: Biosimilars in Hematology and Oncology: Biologics and biosimilars - getting decisions right Rating: 0 out of 5 stars0 ratingsFast Facts: Biosimilares: Biológicos y biosimilares – ¿son lo suficientemente similares? Rating: 0 out of 5 stars0 ratings
Related to Fast Facts
Related ebooks
Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies Rating: 5 out of 5 stars5/5The Path from Biomarker Discovery to Regulatory Qualification Rating: 0 out of 5 stars0 ratingsTarget Validation in Drug Discovery Rating: 0 out of 5 stars0 ratingsCareers in Focus: Pharmaceuticals and Biotechnology, Third Edition Rating: 0 out of 5 stars0 ratingsPharmacoepidemiology and Pharmacovigilance: Synergistic Tools to Better Investigate Drug Safety Rating: 5 out of 5 stars5/5How to Develop Robust Solid Oral Dosage Forms: From Conception to Post-Approval Rating: 0 out of 5 stars0 ratingsBuilding Biotechnology: Biotechnology Business, Regulations, Patents, Law, Policy and Science Rating: 0 out of 5 stars0 ratingsFDA's Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions Rating: 5 out of 5 stars5/5Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care Rating: 0 out of 5 stars0 ratingsAn Overview of FDA Regulated Products: From Drugs and Cosmetics to Food and Tobacco Rating: 5 out of 5 stars5/5Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs Rating: 0 out of 5 stars0 ratingsNonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics Rating: 0 out of 5 stars0 ratingsFood and Drug Regulation in an Era of Globalized Markets Rating: 0 out of 5 stars0 ratingsThe Future of Drug Discovery: Who Decides Which Diseases to Treat? Rating: 0 out of 5 stars0 ratingsPeptide and Protein Delivery Rating: 2 out of 5 stars2/5Prodrug Design: Perspectives, Approaches and Applications in Medicinal Chemistry Rating: 3 out of 5 stars3/5Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics Rating: 0 out of 5 stars0 ratingsPharmacogenomics in Clinical Therapeutics Rating: 0 out of 5 stars0 ratingsMetabolomics for Biomedical Research Rating: 0 out of 5 stars0 ratingsGuidebook for Drug Regulatory Submissions Rating: 0 out of 5 stars0 ratingsPost-Authorization Safety Studies of Medicinal Products: The PASS Book Rating: 0 out of 5 stars0 ratingsBiological Drug Products: Development and Strategies Rating: 0 out of 5 stars0 ratingsPharmacovigilance A Complete Guide - 2020 Edition Rating: 0 out of 5 stars0 ratingsBasic Principles of Drug Discovery and Development Rating: 5 out of 5 stars5/5Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines Rating: 5 out of 5 stars5/5Frontiers in Drug Design & Discovery: Volume 7 Rating: 0 out of 5 stars0 ratingsTranslating Gene Therapy to the Clinic: Techniques and Approaches Rating: 0 out of 5 stars0 ratingsGeneric Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition) Rating: 0 out of 5 stars0 ratingsGlobal Clinical Trials: Effective Implementation and Management Rating: 4 out of 5 stars4/5
Medical For You
Women With Attention Deficit Disorder: Embrace Your Differences and Transform Your Life Rating: 5 out of 5 stars5/5The Vagina Bible: The Vulva and the Vagina: Separating the Myth from the Medicine Rating: 5 out of 5 stars5/5What Happened to You?: Conversations on Trauma, Resilience, and Healing Rating: 4 out of 5 stars4/5Brain on Fire: My Month of Madness Rating: 4 out of 5 stars4/5Mediterranean Diet Meal Prep Cookbook: Easy And Healthy Recipes You Can Meal Prep For The Week Rating: 5 out of 5 stars5/5The Emperor of All Maladies: A Biography of Cancer Rating: 5 out of 5 stars5/5Adult ADHD: How to Succeed as a Hunter in a Farmer's World Rating: 4 out of 5 stars4/5The People's Hospital: Hope and Peril in American Medicine Rating: 4 out of 5 stars4/5Herbal Healing for Women Rating: 4 out of 5 stars4/5The Diabetes Code: Prevent and Reverse Type 2 Diabetes Naturally Rating: 4 out of 5 stars4/5Gut: The Inside Story of Our Body's Most Underrated Organ (Revised Edition) Rating: 4 out of 5 stars4/5The Lost Book of Simple Herbal Remedies: Discover over 100 herbal Medicine for all kinds of Ailment Inspired By Barbara O'Neill Rating: 0 out of 5 stars0 ratingsThe Song of the Cell: An Exploration of Medicine and the New Human Rating: 4 out of 5 stars4/5Working Stiff: Two Years, 262 Bodies, and the Making of a Medical Examiner Rating: 4 out of 5 stars4/5ATOMIC HABITS:: How to Disagree With Your Brain so You Can Break Bad Habits and End Negative Thinking Rating: 5 out of 5 stars5/5Living Daily With Adult ADD or ADHD: 365 Tips o the Day Rating: 5 out of 5 stars5/5Tight Hip Twisted Core: The Key To Unresolved Pain Rating: 4 out of 5 stars4/5"Cause Unknown": The Epidemic of Sudden Deaths in 2021 & 2022 Rating: 5 out of 5 stars5/5The Art of Dying Well: A Practical Guide to a Good End of Life Rating: 4 out of 5 stars4/5A Letter to Liberals: Censorship and COVID: An Attack on Science and American Ideals Rating: 3 out of 5 stars3/5Hidden Lives: True Stories from People Who Live with Mental Illness Rating: 4 out of 5 stars4/5Holistic Herbal: A Safe and Practical Guide to Making and Using Herbal Remedies Rating: 4 out of 5 stars4/5Rewire Your Brain: Think Your Way to a Better Life Rating: 4 out of 5 stars4/5The Hormone Reset Diet: Heal Your Metabolism to Lose Up to 15 Pounds in 21 Days Rating: 4 out of 5 stars4/5
Reviews for Fast Facts
0 ratings0 reviews
Book preview
Fast Facts - P. Cornes
Introduction
Biologics have revolutionized the treatment of many serious disorders, and continue to do so. The first biologics have now reached patent expiry and lower-cost versions – biosimilar medicines – have been developed. The evidence acquired over 10 years of clinical experience, from 30 biosimilar drugs and more than 700 million patient-days’ exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. The potential cost savings that can be realized through the use of biosimilars is putting pressure on clinicians to prescribe these biosimilars in preference to the originator biologic. The use of biosimilars has the potential to increase patient access to effective treatments; however, concerns persist about biosimilars, particularly in therapy areas where biosimilars are relatively recent additions to the formulary.
Fast Facts: Biosimilars addresses these concerns, drawing on the most up-to-date information in this fast-moving area of medicine:
• Is the quality of the biosimilar medicine equivalent to that of the original drug?
• Is the biosimilar medicine safe?
• Which indications can the biosimilar medicine be used for?
• What are the realistic economic benefits?
• How do I switch a patient from a biologic to an equivalent biosimilar medicine?
The answers are supported with a concise explanation of the underlying science and regulatory principles, drawing on the significant experience accumulated within Europe, together with emerging global practice.
This concise authoritative resource will help clinicians and other healthcare decision makers to determine the value of biosimilars in clinical practice and aid discussions with patients.
Terminology is a key issue in the field of biologics and biosimilars, with terms often used incorrectly, causing confusion (see page 12 for examples). Definitions of these terms are provided in Table 1.1.
Biologics
Biologics are large macromolecules, typically proteins. They range in size and structural complexity from simple proteins such as insulin and growth hormone to complex molecules such as coagulation factors and monoclonal antibodies, as shown in Figure 1.1. Many biologics, particularly the monoclonal antibodies, are described as targeted therapies because they have been designed to interact with specific receptors on cells.
Biologics are created in living systems, such as bacterial, animal or human cell cultures, or are extracted from whole organisms; they cannot be synthesized chemically. Most biologics are complex mixtures; whilst their primary and secondary structures are known, they are less easily characterized at the tertiary level. This stands in contrast to conventional ‘small molecule’ drugs, which usually have a unique structure that can be fully characterized and are typically produced by inexpensive chemical synthesis that is straightforward to replicate. The complex nature of the biologics, and their manufacturing processes, means that identical copies of these molecule cannot be created.
Figure 1.1 Examples of the varying complexity of biologics¹
Biosimilar medicines
A biosimilar, as its name suggests, is highly similar to the reference biologic product, but is not identical. The primary and secondary amino acid structure, dosing, and route of administration are the same; differences in formulation, presentation, and the administration device are permitted, provided that these differences do not affect safety or effectiveness. As with all biologic medicines, the challenge for manufacturers and regulators is to ensure that copies of biologics are close enough in structure and function to the reference product to have no clinically meaningful differences in practical